Business Context and Reporting Period
Company: Tempest Therapeutics, Inc. (TPST)
Filing Type: Form 8-K (Current Report)
Date of Report: November 19, 2025
Event: Entry into a Material Definitive Agreement (Asset Purchase Agreement) with Erigen LLC and Factor Bioscience Inc. to acquire four CAR T-cell therapy assets. The transaction is subject to stockholder approval and a pre-closing equity financing of at least $5.0 million, with closing expected in early 2026.
Key Financial Metrics and Transaction Terms
- Consideration: 8,268,495 shares of Company Common Stock issued to Erigen on behalf of the Sellers.
- Ownership Structure (Post-Closing): Pre-closing equityholders will own approximately 35.0%; Erigen equityholders (Matt Angel, Ph.D. and Lotus Capital) are expected to own approximately 38.0% and 27.0%, respectively.
- Warrant Dividend: One warrant per share of Common Stock held as of the record date, exercisable at $18.48 per share, with a five-year term.
- Financing Requirement: Closing is conditioned on an equity financing resulting in gross proceeds of at least $5.0 million.
- Termination Fee: $300,000 payable to Sellers under specified termination circumstances.
- Executive Compensation (New CEO): Dr. Matt Angel to receive a $650,000 annual base salary, a target annual bonus of 50% of base, and an option to purchase 2% of outstanding shares (vesting over four years).
Material Changes Versus Prior Period
This filing represents a strategic pivot rather than a standard periodic financial update. Material changes include:
- Asset Expansion: Acquisition of four new CAR T-cell therapy assets (ERI-2003, ERI-2206, ERI-3003, ERI-3206), expanding the pipeline beyond existing candidates amezalpat and TPST-1495.
- Management Transition: Stephen Brady to step down as CEO/President and become Chairman; Dr. Matt Angel to be appointed CEO/President and Board Member. Geoff Nichol to resign from the Board.
- Capital Structure: Significant dilution to existing shareholders via the issuance of ~8.27 million shares and a warrant dividend.
Guidance, Outlook, and Risks
Outlook and Pipeline Strategy
- Amezalpat: Pursue business development or financing for pivotal development in first-line liver cancer (HCC).
- TPST-1495: Support a Phase 2 study in Familial Adenomatous Polyposis (expected late 2026/early 2027), funded by the National Cancer Institute.
- TPST-2003 (formerly ERI-2003): Leverage Phase 1b/1/2a data from China to pursue preclinical comparability and U.S. IND submission.
- TPST-2206, TPST-3003, TPST-3206: Advance preclinical activities with potential for future clinical development.
Risks and Contingencies
- Closing Conditions: Transaction requires stockholder approval and successful completion of the $5.0 million pre-closing financing by December 5, 2025.
- Termination Deadlines: Agreement may be terminated if closing does not occur by March 19, 2026.
- Operational Risks: Integration of assets, regulatory approvals, and ability to secure additional capital for development.
- Lock-Up: Sellers are restricted from transferring 50% of their acquired shares for 180 days post-closing.
Investor Verification Checklist
- Verify the status of the required $5.0 million pre-closing equity financing.
- Confirm the outcome of the upcoming stockholder vote on the Asset Purchase Agreement.
- Review the full Asset Purchase Agreement (Exhibit 10.1) for specific representations, warranties, and indemnification terms.
- Monitor the timeline for the warrant dividend distribution and the $18.48 exercise price relative to current market conditions.
- Assess the clinical data status of the acquired assets, particularly the Chinese trial data for TPST-2003.